Coramitug is well tolerated and leads to a statistically significant reduction in N-terminal pro-brain type natriuretic peptide (NT-proBNP)—a marker of disease progression in transthyretin-mediated ...
The mean cost savings associated with tafamidis treatment due to a reduction in hospitalization because of heart failure and shortening of length of stay in the hospital was $12,940 per patient.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback